CTMX Latest Headlines

Top CytomX Executives Quietly Unload Shares in a Wave of Insider Selling

at www.tipranks.com (Thu, 19-Mar 10:06 PM)

CytomX Therapeutics Raises $234 Million in Equity Offering

at www.tipranks.com (Thu, 19-Mar 4:33 PM)

Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), CytomX Therapeutics (CTMX) and Johnson & Johnson (JNJ)

at www.tipranks.com (Thu, 19-Mar 4:40 AM)

CytomX Therapeutics’ $250 Million Equity Offering Strengthens Pipeline for Next-Generation Cancer Treatments

Market Chameleon (Wed, 18-Mar 7:06 AM)

CytomX Therapeutics prices $250M public offering at $5.30 per share

at seekingalpha.com (Wed, 18-Mar 1:39 AM)

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), CytomX Therapeutics (CTMX) and Zoetis (ZTS)

at www.tipranks.com (Tue, 17-Mar 7:20 AM)

CytomX Therapeutics Confronts Rising AI Regulatory Risks and Cost Pressures

at www.tipranks.com (Tue, 17-Mar 2:01 AM)

CytomX's Varsetatug Masetecan Shows 32% Response Rate in Late-Line Colorectal Cancer—Phase 1 Data Highlights Emerging Potential

Market Chameleon (Mon, 16-Mar 9:53 AM)

CytomX’s 2025 Results Show Strong Financial Position as Pipeline Advances Toward Pivotal Data

Market Chameleon (Mon, 16-Mar 7:29 AM)

CytomX Therapeutics launches $250M public offering

at seekingalpha.com (Mon, 16-Mar 4:26 PM)

Varseta-M’s Differentiated Efficacy in Late-Line Colorectal Cancer Drives Higher Approval Odds and Upside to Target Price

at www.tipranks.com (Mon, 16-Mar 12:25 PM)

J.P. Morgan outlines CRM options play for uncertain Iran war outcome

at seekingalpha.com (Mon, 16-Mar 12:18 PM)

CytomX outlines registrational trial plans for Varseta-M in third-line colorectal cancer with initial study start in 2027

at seekingalpha.com (Mon, 16-Mar 12:05 PM)

Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform

at www.tipranks.com (Mon, 16-Mar 9:00 AM)

Options Volatility and Implied Earnings Moves Today, March 16, 2026

at www.tipranks.com (Mon, 16-Mar 8:05 AM)

CytomX Schedules March 16, 2026 for Full-Year 2025 Results: Focus Sharpens on Pipeline Progress and Oncology Partnerships

Market Chameleon (Wed, 4-Mar 9:29 AM)

CytomX Therapeutics to Spotlight Novel Oncology Technologies at February Conferences

Market Chameleon (Wed, 4-Feb 8:54 AM)